217 related articles for article (PubMed ID: 24710131)
1. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial.
Ajeganova S; Svensson B; Hafström I;
BMJ Open; 2014 Apr; 4(4):e004259. PubMed ID: 24710131
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study.
Hafström I; Engvall IL; Rönnelid J; Boonen A; van der Heijde D; Svensson B;
BMJ Open; 2014 Jul; 4(7):e005246. PubMed ID: 25079933
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study.
Innala L; Möller B; Ljung L; Magnusson S; Smedby T; Södergren A; Öhman ML; Rantapää-Dahlqvist S; Wållberg-Jonsson S
Arthritis Res Ther; 2011 Aug; 13(4):R131. PubMed ID: 21843325
[TBL] [Abstract][Full Text] [Related]
4. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.
So H; Lam TO; Meng H; Lam SHM; Tam LS
Ann Rheum Dis; 2023 Nov; 82(11):1387-1393. PubMed ID: 37487608
[TBL] [Abstract][Full Text] [Related]
5. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
ter Wee MM; den Uyl D; Boers M; Kerstens P; Nurmohamed M; van Schaardenburg D; Voskuyl AE; Lems WF
Ann Rheum Dis; 2015 Jun; 74(6):1233-40. PubMed ID: 24818633
[TBL] [Abstract][Full Text] [Related]
6. Anti-Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis.
Westerlind H; Rönnelid J; Hansson M; Alfredsson L; Mathsson-Alm L; Serre G; Cornillet M; Holmdahl R; Jakobsson PJ; Skriner K; Klareskog L; Saevarsdottir S; Askling J
Arthritis Rheumatol; 2020 Oct; 72(10):1658-1667. PubMed ID: 32475073
[TBL] [Abstract][Full Text] [Related]
7. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
Gonzalez A; Maradit Kremers H; Crowson CS; Ballman KV; Roger VL; Jacobsen SJ; O'Fallon WM; Gabriel SE
Ann Rheum Dis; 2008 Jan; 67(1):64-9. PubMed ID: 17517756
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.
Davis LA; Cannon GW; Pointer LF; Haverhals LM; Wolff RK; Mikuls TR; Reimold AM; Kerr GS; Richards JS; Johnson DS; Valuck R; Prochazka A; Caplan L
J Rheumatol; 2013 Jun; 40(6):809-17. PubMed ID: 23547211
[TBL] [Abstract][Full Text] [Related]
9. Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.
Sparks JA; Lesperance T; Accortt NA; Solomon DH
Arthritis Care Res (Hoboken); 2019 Apr; 71(4):512-520. PubMed ID: 29799667
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
[TBL] [Abstract][Full Text] [Related]
11. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Boers M; Verhoeven AC; Markusse HM; van de Laar MA; Westhovens R; van Denderen JC; van Zeben D; Dijkmans BA; Peeters AJ; Jacobs P; van den Brink HR; Schouten HJ; van der Heijde DM; Boonen A; van der Linden S
Lancet; 1997 Aug; 350(9074):309-18. PubMed ID: 9251634
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.
Naranjo A; Sokka T; Descalzo MA; Calvo-Alén J; Hørslev-Petersen K; Luukkainen RK; Combe B; Burmester GR; Devlin J; Ferraccioli G; Morelli A; Hoekstra M; Majdan M; Sadkiewicz S; Belmonte M; Holmqvist AC; Choy E; Tunc R; Dimic A; Bergman M; Toloza S; Pincus T;
Arthritis Res Ther; 2008; 10(2):R30. PubMed ID: 18325087
[TBL] [Abstract][Full Text] [Related]
13. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008.
Kerola AM; Nieminen TV; Virta LJ; Kautiainen H; Kerola T; Pohjolainen T; Kauppi MJ; Puolakka K
Clin Exp Rheumatol; 2015; 33(3):391-8. PubMed ID: 25936374
[TBL] [Abstract][Full Text] [Related]
14. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis.
Kawashima H; Kagami SI; Kashiwakuma D; Takahashi K; Yokota M; Furuta S; Iwamoto I
Rheumatol Int; 2017 Mar; 37(3):369-376. PubMed ID: 27999943
[TBL] [Abstract][Full Text] [Related]
15. Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
Solomon DH; Reed GW; Kremer JM; Curtis JR; Farkouh ME; Harrold LR; Hochberg MC; Tsao P; Greenberg JD
Arthritis Rheumatol; 2015 Jun; 67(6):1449-55. PubMed ID: 25776112
[TBL] [Abstract][Full Text] [Related]
16. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects.
Hansen M; Podenphant J; Florescu A; Stoltenberg M; Borch A; Kluger E; Sørensen SF; Hansen TM
Ann Rheum Dis; 1999 Nov; 58(11):713-8. PubMed ID: 10531077
[TBL] [Abstract][Full Text] [Related]
17. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
18. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.
Davis JM; Maradit Kremers H; Crowson CS; Nicola PJ; Ballman KV; Therneau TM; Roger VL; Gabriel SE
Arthritis Rheum; 2007 Mar; 56(3):820-30. PubMed ID: 17330254
[TBL] [Abstract][Full Text] [Related]
20. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
